- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such ...

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression ...

- Largest ever PSP clinical trial will evaluate the efficacy and safety of AMX0035 in adults with PSP compared to placebo “There is a pressing unmet need within the PSP community for new and effective ...

The recent discovery of a unique protein pattern in spinal fluid may make earlier diagnosis of progressive supranuclear palsy a reality. Researchers at the University of California San Francisco (CA, ...

LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...

A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder ...

A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder ...

These findings indicate that PSP pathology affects gait control pathways that are also affected in PD. Gait changes associated with defective scaling of stride length and postural instability were ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in ORION, a randomized, ...